Immuron Narrows Losses Amid R&D Push, Eyes Future Financing

TL;DR

**Immuron's cash burn is still a major concern, but narrowing losses and clinical progress offer a glimmer of hope for this speculative biotech play.**

AI Summary

Immuron Ltd (IMRN) reported a net loss of A$5,215,987 for the fiscal year ended June 30, 2025, an improvement from A$6,936,957 in 2024 and A$3,786,507 in 2023. The company's accumulated deficit reached A$82,443,205 as of June 30, 2025, reflecting continuous operating losses since its inception in 1994. Immuron is a commercial and clinical-stage biopharmaceutical company focused on polyclonal antibodies, with flagship commercial products Travelan and Protectyn sold in Australia and Travelan in Canada and the U.S. as a dietary supplement. Key business changes include ongoing expansion of research and development for infectious diseases and the advancement of lead drug candidates IMM-124E for Traveler's Diarrhea and IMM-529 for C. difficile into clinical development. The company held A$2,830,526 in cash and cash equivalents as of June 30, 2025, and anticipates needing additional financing to support its long-term objectives, including clinical trials and commercialization efforts. Risks include the uncertainty of clinical trial outcomes, reliance on a sole manufacturer, and the need to achieve market acceptance for its products.

Why It Matters

Immuron's continued operating losses and accumulated deficit of A$82.4 million highlight the significant capital demands of biopharmaceutical R&D. For investors, the ability to secure additional financing will be critical for advancing IMM-124E and IMM-529 through clinical trials and achieving profitability, especially given the competitive landscape in infectious disease treatments. Employees and customers will be impacted by the success or failure of these clinical programs and the commercial expansion of Travelan and Protectyn. The broader market will watch to see if Immuron's novel polyclonal antibody platform can disrupt existing treatment paradigms for common infections like Traveler's Diarrhea and C. difficile, potentially offering safer alternatives.

Risk Assessment

Risk Level: high — Immuron has incurred operating losses every period since 1994, with an accumulated deficit of A$82,443,205 as of June 30, 2025. The company's cash and cash equivalents stood at only A$2,830,526, indicating a high probability of needing significant additional financing to fund ongoing and future clinical trials for IMM-124E and IMM-529, and to achieve profitability.

Analyst Insight

Investors should monitor Immuron's progress in securing additional financing and the outcomes of its clinical trials for IMM-124E and IMM-529. Given the high-risk profile and historical losses, a cautious approach is warranted, focusing on any concrete milestones in product development and market acceptance.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

A$-5,215,987

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

A$2,830,526

revenue Growth

Not Disclosed

Executive Compensation

Key Numbers

• A$5,215,987 — Net Loss (Fiscal year ended June 30, 2025, an improvement from A$6,936,957 in 2024.)
• A$82,443,205 — Accumulated Deficit (As of June 30, 2025, reflecting continuous operating losses since 1994.)
• A$2,830,526 — Cash and Cash Equivalents (As of June 30, 2025, indicating need for additional financing.)
• 233,959,013 — Outstanding Ordinary Shares (As of June 30, 2025.)
• 40 — Ordinary Shares per ADS (Each American Depositary Share represents 40 ordinary shares.)

Key Players & Entities

• Immuron Ltd (company) — Registrant
• Steven Lydeamore (person) — Chief Executive Officer
• Travelan (company) — Flagship commercial product
• Protectyn (company) — Commercial product
• IMM-124E (company) — Lead drug candidate for Traveler's Diarrhea
• IMM-529 (company) — Lead drug candidate for C. difficile infections
• NASDAQ Stock Market LLC (regulator) — Exchange for ADSs
• Australian Securities Exchange (regulator) — Exchange for ordinary shares
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company has a history of operating losses and an accumulated deficit of A$82,443,205 as of June 30, 2025. With A$2,830,526 in cash and cash equivalents, Immuron anticipates needing additional financing to support its long-term objectives, including clinical trials and commercialization efforts.
• Reliance on Sole Manufacturer [medium — operational]: Immuron relies on a single manufacturer for its products. This sole-source dependency creates a significant operational risk, as any disruption at the manufacturer's facility could lead to supply chain issues and impact product availability.
• Clinical Trial Uncertainty [high — regulatory]: The advancement of lead drug candidates IMM-124E and IMM-529 into clinical development carries inherent risks. The outcomes of clinical trials are uncertain and can significantly impact the company's ability to achieve market acceptance and commercial success for these potential new products.
• Market Acceptance of Products [medium — market]: Achieving market acceptance for Immuron's products, including Travelan and Protectyn, is crucial for revenue generation. Factors such as competition, pricing, and physician/consumer adoption rates will determine the commercial success of these offerings.

Industry Context

Immuron operates in the biopharmaceutical sector, specifically focusing on the development and commercialization of polyclonal antibodies. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on external financing to fund clinical trials and commercialization efforts.

Regulatory Implications

Immuron's products, particularly those in clinical development like IMM-124E and IMM-529, are subject to stringent regulatory review by bodies such as the FDA. The classification of Travelan as a dietary supplement in the U.S. and Canada implies a different regulatory framework than for prescription drugs, but still requires adherence to manufacturing and labeling standards.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate clinical trial progress and outcomes.
3. Assess commercial performance of Travelan and Protectyn.

Key Dates

• 2025-06-30: Fiscal Year End — Reported net loss of A$5,215,987 and accumulated deficit of A$82,443,205. Cash and cash equivalents stood at A$2,830,526.
• 1994-01-01: Company Inception — Marks the beginning of the company's operations, leading to the current accumulated deficit of A$82,443,205.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception that have not been offset by profits. (Immuron has an accumulated deficit of A$82,443,205 as of June 30, 2025, indicating a long history of operating losses.)

Polyclonal Antibodies

Antibodies produced by many different B cells, recognizing multiple epitopes on a single antigen. (This is the core technology Immuron focuses on for its therapeutic products.)

American Depositary Share (ADS)

A U.S. dollar-denominated equity share of a foreign-based company available for purchase in the U.S. stock market. (Each ADS represents 40 ordinary shares of Immuron Ltd, impacting share price and trading dynamics.)

Dietary Supplement

A product intended to supplement the diet, containing one or more dietary ingredients (including vitamins, minerals, herbs or other botanicals, amino acids, and substances like enzymes, organ tissues, glandulars, and metabolites). (Travelan is sold as a dietary supplement in the U.S. and Canada, which has different regulatory pathways than pharmaceutical drugs.)

Year-Over-Year Comparison

The fiscal year ended June 30, 2025, shows a reduced net loss of A$5,215,987 compared to A$6,936,957 in the prior year, indicating some operational improvement. However, the accumulated deficit continues to grow, reaching A$82,443,205, underscoring the ongoing need for capital. Cash reserves remain modest at A$2,830,526, reinforcing the critical need for future financing.

Key Financial Figures

• $5,215,987 — 994 and we have reported net losses of A$5,215,987, A$6,936,957 and A$3,786,507 during the
• $6,936,957 — ve reported net losses of A$5,215,987, A$6,936,957 and A$3,786,507 during the fiscal years
• $3,786,507 — losses of A$5,215,987, A$6,936,957 and A$3,786,507 during the fiscal years ended June 30,
• $82,443,205 — 30, 2025, our accumulated deficit was A$82,443,205. We may continue to incur additional op
• $2,830,526 — opments. As of June 30, 2025, we had A$2,830,526 in cash and cash equivalents. Developin

Filing Documents

• ea0245648-20f_immuron.htm (20-F) — 2217KB
• ea024564801ex4-7_immuron.htm (EX-4.7) — 95KB
• ea024564801ex4-9_immuron.htm (EX-4.9) — 325KB
• ea024564801ex11-1_immuron.htm (EX-11.1) — 744KB
• ea024564801ex12-1_immuron.htm (EX-12.1) — 10KB
• ea024564801ex12-2_immuron.htm (EX-12.2) — 10KB
• ea024564801ex13-1_immuron.htm (EX-13.1) — 4KB
• ea024564801ex13-2_immuron.htm (EX-13.2) — 4KB
• ea024564801ex23-1_immuron.htm (EX-23.1) — 2KB
• ea024564801ex23-2_immuron.htm (EX-23.2) — 9KB
• ea024564801ex23-3_immuron.htm (EX-23.3) — 6KB
• image_001.jpg (GRAPHIC) — 19KB
• image_002.jpg (GRAPHIC) — 18KB
• image_003.jpg (GRAPHIC) — 14KB
• image_004.jpg (GRAPHIC) — 73KB
• image_005.jpg (GRAPHIC) — 6KB
• image_006.jpg (GRAPHIC) — 6KB
• image_007.jpg (GRAPHIC) — 21KB
• ex11-1_001.jpg (GRAPHIC) — 11KB
• ex23-2_001.jpg (GRAPHIC) — 7KB
• 0001213900-25-091414.txt ( ) — 11482KB
• imrn-20250630.xsd (EX-101.SCH) — 116KB
• imrn-20250630_cal.xml (EX-101.CAL) — 70KB
• imrn-20250630_def.xml (EX-101.DEF) — 387KB
• imrn-20250630_lab.xml (EX-101.LAB) — 717KB
• imrn-20250630_pre.xml (EX-101.PRE) — 412KB
• ea0245648-20f_immuron_htm.xml (XML) — 1634KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No INTRODUCTION We are a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. This is a large addressable market which continues to grow as we seek to increase sales of our existing commercial products and to expand our product portfolio and distribution capability. We currently market our flagship commercial product Travelan, and Protectyn in Australia, where both products are listed medicines on the Australian Register for Therapeutic Goods. Travelan (AUST L 106709) is an over-the-counter product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial and is sold in pharmacies throughout Australia. Protectyn (AUST L 231001) is currently sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. We also market Travelan (NPN 80046016) in Canada where it is licensed as a natural health product indicated to reduce the risk of travelers' diarrhea, and presently market Travelan in the U.S. as a dietary supplement for digestive tract protection. Our polyclonal antibodies offer delivery within the gastrointestinal ("GI") tract and do not cross into the bloodstream, potentially leading to improved safety and tolerability, without sacrificing efficacy. Our technology platform can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces. We believe that our lead drug candidates currently entering the clinical development phase have the potential to transform the existing treatment paradigms for Enteroto

Business

Business Overview 24 C. Organizational Structure 38 D. Property, Plant and Equipment 39 ITEM 4A. UNRESOLVED STAFF COMMENTS 39 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 39 A. Operating Results 39 B. Liquidity and Capital Resources 43 C. Research and Development, Patents and Licenses 46 D. Trend Information 47 E Critical Accounting Estimates 47 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 48 A. Directors and Senior Management 48 B. Compensation 50 C. Board Practices 62 D. Employees 63 E. Share 64 F. Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation 64 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 65 A. Major Shareholders 65 B. Related Party Transactions 65 C. Interests of Experts and Counsel 65 ITEM 8. FINANCIAL INFORMATION 66 A. Financial 66 B. Significant Changes 66 ITEM 9. THE OFFER AND LISTING 66 A. Offer and Listing Details 66 B. Plan of Distribution 66 C. Markets 66 D. Selling Shareholders 66 E.

Dilution

Dilution 66 F. Expenses of the Issue 66 ITEM 10. ADDITIONAL INFORMATION 67 A. Share Capital 67 B. Memorandum and Articles of Association 67 C. Material Contracts 71 D. Exchange Controls 71 E. Taxation 72 F. Dividends and Paying Agents 77 G. by Experts 77 H. Documents on Display 77 I. Subsidiary Information 78 J. Annual Report to Security Holders 78 i ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 78 ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 78 A. Debt Securities 78 B. Warrants and Rights 78 C. Other Securities 78 D. American Depositary Shares 79 PART II 80 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 80 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 80 ITEM 15. CONTROLS AND PROCEDURES 80 A. Disclosure

Controls and Procedures

Controls and Procedures 80 B. Management's Report on Internal Control over Financial Reporting 80 C. Attestation Report of the Registered Public Accounting Firm 80 D. Changes in Internal Control over Financial Reporting 80 ITEM 16. RESERVED 81 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 81 ITEM 16B. CODE OF ETHICS 81 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 81 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 82 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 82 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 82 ITEM 16G. CORPORATE GOVERNANCE 82 ITEM 16H. MINE SAFETY DISCLOSURE 82 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 82 ITEM 16J. INSIDER TRADING POLICIES 83 ITEM 16K. CYBERSECURITY 83 PART III 84 ITEM 17. FINANCIAL 84 ITEM 18. FINANCIAL 84 ITEM 19. EXHIBITS 85 SIGNATURE 86 ii PART I

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable.

KEY INFORMATION

ITEM 3. KEY INFORMATION A. [RESERVED] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Investing in our ADSs involves a high degree of risk and uncertainty. You should carefully consider the risks and uncertainties described below before investing in our ADSs. Additional risks and uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the following risks actually occurs, our business, prospects, financial condition and results of operations could be harmed. In that case, the price of our ADSs could decline, and you could lose all or part of your investment. Summary of Risk Factors The following summarizes some, but not all, of the risks provided below. Please carefully consider all of the information discussed in this Item 3.D. "Risk Factors" in this annual report for a more thorough description of these and other risks: Summary of Risks Related to Our Financial Condition As a company undertaking research and development activities of our existing patent portfolio we have incurred operating losses; we may continue to incur operating losses for the foreseeable future and may never achieve or maintain profitability. Summary of Risks Related to Our Business Clinical trials are expensive and time consuming, and their outcome is uncertain. We may not be successful in obtaining or maintaining other rights necessary for the development of our pipeline through acquisitions and in- licenses. We grant licenses to our collaborators to use our hyper-immune colostrum technology exclusively for the development of product candidates for certain conditions. We may not be able to complete the development of IMM-124E, IMM-529 or develop other pharmaceutical products. Our research and development efforts will be seriously jeopardized if we are unable to retain key personnel and cultivate key academic and s

View Full Filing

View this 20-F filing on SEC EDGAR